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Background

Case Presentation

• Acute myeloid leukemia (AML)
is arrested maturation and
uncontrolled proliferation of a group
1
of hematopoietic progenitor cells.
Clinical presentation varies (Table 1).
• Leukemia cutis(LC)  is invasion of
neoplastic precursors into different
layers of the skin commonly
associated with underlying systemic
disease, first described in 1895 by
5-6
Hindenberg and Hirschlaff.
• If LC develops prior to blasts
appearing in peripheral blood or bone
marrow, it is aleukemic leukemia
cutis (ALC). ALC is extremely difficult
to diagnose clinically and early
recognition is essential for initiation of
treatment.

Discussion:

• A 59 year-old-female presents with generalized weakness, low grade fevers and weight loss over 2
months with bilateral ankle arthralgias and maculopapular, nonpruritic rash on abdomen (Image 1)
developing after ~1.5 months.  
• Peripheral blood (image 2)showed leukocytosis with 70% monocytes but flow cytometry showed fully
mature cells with no aberrant phenotype. Comprehensive rheumatologic, infectious and endocrine workups were negative.
• Skin biopsy (image 3) showed a mononuclear cell infiltrate, with round/slightly convoluted nuclei,
moderately dispersed chromatin consistent with leukemia cutis.
• Bone marrow biopsy (image 4) showed 82% blasts expressing monocytic markers consistent with acute
monoblastic (M5) leukemia, +FLT3-ITD, NPM1 and -CEBPA, CD34.
• Right sided facial droop developed. LP negative for leukemic involvement.
• 7+3 induction chemotherapy with idarubicin and cytarabine initiated. In remission at 3 month followup. To bridge for allogeneic stem cell transplant, 2 cycles of high dose cytarabine and 1 cycle decitabine
were administered.

• AML is the clinical expansion of >20% myeloid blasts in peripheral AML should be suspected in
7
patients presenting with skin
blood or bone marrow that involve one or all myeloid lineage.
   – Classified into favorable, intermediate, and unfavorable based on
lesions, low grade fevers, weight
cytogenetics.1
loss and leukocytosis despite lack
of leukemic cells in peripheral
• Skin manifestation of AML are rare, occurring 5-15% adults and
7-8
blood. Treatment should not be
more common in M5 with ~10-30% skin  involvement.
5
delayed and initiated based on
   – LC is more common in systemic disease, occurring aleukemic in 7%.
  
• ALC : skin infiltration prior to appearance in blood or bone marrow  
skin biopsy.
by~1 month.5

• Skin lesions vary making diagnosis difficult without a biopsy.
(Table 2)
  
  
  

  

2-4

– L
 C represent aggressive disease, higher tumor burden with poor
prognosis, but shorter time to remission.7-9
– Increase risk for relapse and new skin lesions require re-biopsy.9
– CD markers associated with AML M5 with LC are + CD45, 56, 33, 4
and – CD117, 68, 34, MPO.7

• ALC should prompt  bone marrow biopsy and chemotherapy
initiation irrespective to bone marrow status.
  

Table 1. Clinical Presentaiton of AML

  

– S
 tem cell transplant considered in first remission with other prognostic
factors.9
– Chemotherapy may induce remission in bone marrow but not with
LC.9
– Palliative radiation can help with pruritus.9

• Pancytopenia complications

Table 2. Leukemia Cutis Characteristics

       • Anemia: fatigue, weakness, skin pallor
       • Thrombocytopenia: gingival bleeding, ecchymosis, epistaxis, petechiae
       • Leukopenia: varying degrees of infections

Size/Shape

• Extramedullary sites
       • Gingival infiltrates
       • Cutaneous lesions: vasculitis, Leukemia Cutis
       • Myeloid sarcoma: intestines, mediastinum, uterus, ovary, lymph nodes, orbit

• Bone Pain/Arthralgias
• CNS involvement: headache, facial nerve palsies, motor deficits
• Fever: infection > leukemia
• Adenopathy: palpable and significant enlargement is rare
• Organomegaly

Image 1. Maculopapular,
erythematous/violaceous, nonpruritic rash that erupted gradually
on patient abdomen and back prior
to spreading to the extremities.
Rash did not improve with systemic
steroids but resolved with 7+3
induction chemotherapy.

Image 2. Peripheral blood smear
shows large amount of mature
monocytes with no evidence of
dysplasia (A).  Smear was taken same
time as skin biopsy. Flow cytometry
indicates the large monocyte
population (B).

Image 3. Skin biopsy shows monocytic infiltrate
consistent with leukemia cutis with the dermis
exhibiting overwhelming immature monocytic
infiltrates positive for MPO,CD68, CD45, CD33,
CD68, CD4. Biopsy was performed after 3
weeks of maculopapular rash present with a
peripheral blood smear that showed only mature
monocytosis.

Image 4. Bone marrow biopsy with 82% monoblasts
with diminished maturation. +CD56 and –CD117
assist with the M5 AML diagnosis. +FLT3 ITD, NPM1
and – CEBPA, confirming with a poor prognosis and
aggressive disease.  

Conclusion:

Color

Distribution

Macules

Solitary

Red

Lower Extremity

Papules
Plaques

Multiple

Brown

Upper Extremity

Violaceous

Trunk/Face

Nodules
Ulcers

5,7-9

Blueberry (infants)
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• Areas of inflammation/trauma
• Physiologic response to specific chemotactic factors
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